Literature DB >> 20514618

Novel homozygous mutation (c.175delG) in platelet glycoprotein ITGA2B gene as cause of Glanzmann's thrombasthenia type I.

C Vannier1, W Behnisch, I Bartsch, K Sandrock, F Ertle, K Schmidt, A Busse, A Superti-Furga, A Kulozik, S Santoso, B Zieger.   

Abstract

BACKGROUND: Glanzmann's thrombasthenia (GT), is a rare autosomal recessive bleeding disorder. Platelets from patients with GT show quantitative or qualitative defects of the platelet membrane glycoprotein (GP) IIb/IIIa complex. A variety of genetic defects in ITGA2B and ITGB3 (genes for GPIIb and GPIIIa) has been described causing the clinical entity of GT. PATIENTS: A newborn with bleeding symptoms (petechiae) platelet analyses revealed an inherited primary hemostasis disorder. METHODS/
RESULTS: Analyses of patient's platelets using flow cytometry and immunoblotting showed absence of GPIIb protein and reduced amount of GPIIIa. Using restriction fragment length polymorphism heterozygosity for the deletion could be identified in the parents and in two siblings. Expression studies in mammalian cells revealed that the mutant GPIIb is missing and additionally affects the expression of wildtype GPIIIa. This deletion leads to a truncation at the very N-terminal region of the GPIIb protein.
CONCLUSION: The present study describes a patient with GT associated with a novel homozygous deletion (c.175delG) in exon 1 of ITGA2B. This deletion led to a reading frameshift and caused a severely truncated form of GPIIb.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514618     DOI: 10.1055/s-0030-1249064

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  1 in total

1.  Functional comparison of induced pluripotent stem cell- and blood-derived GPIIbIIIa deficient platelets.

Authors:  Mathias Orban; Alexander Goedel; Jessica Haas; Kirstin Sandrock-Lang; Florian Gärtner; Christian Billy Jung; Barbara Zieger; Elvira Parrotta; Karin Kurnik; Daniel Sinnecker; Gerhard Wanner; Karl-Ludwig Laugwitz; Steffen Massberg; Alessandra Moretti
Journal:  PLoS One       Date:  2015-01-21       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.